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1,2,4-TriazolesAbstract This paper describes the synthesis of a new series of 1,3,5-trisubstituted-1,2,4-triazoles by
1,3-dipolar cycloaddition reaction of C-phenyl-aminocarbonyl-N-arylnitrilimines with guanidine
derivatives. The structures of the newly synthesized compounds were elucidated by spectral meth-
ods (IR, 1H NMR, 13C NMR and MS spectroscopy) and elemental analysis. The microbial features
of the synthesized compounds were studied using well-established methods from the literature.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
A literature survey revealed azole derivatives belonging to an
important group of heterocyclic compounds that have a long
history in pharmaceutical and medicinal chemistry. In particu-
lar, triazoles represent a class of heterocyclic compounds with a
wide variety of biological activities (Dogan et al., 2005; Amir
and Kumar, 2007; Tozkoparan et al., 2007; Ezabadi et al.,
2008; Ku¨c¸u¨kgu¨zel et al., 2008; Sakac et al., 2009; Sun et al.,
2010; Jyothi et al., 2010; Rama et al., 2010). Furthermore, fused
heterocyclic compounds containing a 1,2,4-triazole nucleus
have a broad spectrum of pharmacological activities, includinganti-inﬂammatory (Husain and Naseer, 2011; Aytac et al.,
2009), analgesic (Aytac et al., 2009), ulcerogenic (Amir et al.,
2008; Reddy et al., 2010), antimicrobial (Amir et al., 2008;
Reddy et al., 2010; Sztanke et al., 2008), anticancer (Sztanke
et al., 2008; Badr and Barwa, 2011), antiproliferative and
apoptotic properties (Sztanke et al., 2008). The synthesis of
compounds whose structure contains 1,2,4-triazole rings has
attracted widespread attention. 1,3-Dipolar cycloaddition is
one of the most versatile methods for the construction of
ﬁve-membered heterocycles (Padwa, 1991). Recently, we have
described a versatile and efﬁcient one-pot synthesis of
dispiroheterocycles containing 1,2,4-triazole moieties utilizing
available keto oximes, hydrazones, and hydrazonoyl halides
(Dalloul and Abu Samaha, 2010). Considering the promising
opportunities that the synthesis of such heterocycles might
open with regard to the production of biologically active
nitrogen, the present study represents a continuation of our
previous work in an attempt to search for and synthesize a
biologically active nitrogen heterocycle (Yuksek et al., 1997;
Table 1 Physical data, molecular ion peaks and elemental analysis for compounds 5a–j.
Cpd. No. Mol. Formula (MW) Yield: mg (%) Mp.±2 (C) Analysis (%), Calcd./Found [M+]
C H N
5a C15H13N5O 0.0021 173 64.51 4.69 25.07 279
(279.30) (76) (64.75) (4.80) (24.95)
5b C15H12ClN5O 0.0022 184 57.42 3.86 22.32 313/315
(313.75) (72) (57.60) (3.70) (22.45)
5c C15H12BrN5O 0.0028 163 50.30 3.38 19.55 358/360
(358.20) (78) (50.55) (3.20) (19.65)
5d C15H12FN5O 0.0021 171 60.60 4.07 23.56 297/299
(297.29) (73) (60.35) (3.90) (23.40)
5e C16H15N5O 0.0022 189 65.52 5.15 23.88 293
(293.33) (75) (65.75) (5.00) (24.00)
5f C21H17N5O 0.0025 187 70.97 4.82 19.71 355
(355.40) (72) (70.75) (4.95) (19.55)
5g C21H16ClN5O 0.0027 212 64.70 4.14 17.96 389/391
(389.85) (71) (64.50) (4.30) (18.10)
5h C21H16BrN5O 0.003 193 58.08 3.71 16.13 434/436
(434.30) (70) (57.85) (3.60) (16.30)
5i C21H16FN5O 0.0026 188 67.55 4.32 18.76 373/375
(373.39) (69) (67.70) (4.20) (18.60)
5j C22H19N5O 0.0023 241 71.53 5.18 18.96 369
(369.43) (63) (71.30) (5.00) (19.15)
Heterocyclic synthesis using nitrilimines: Part 19. Synthesis of novel 1,3,5-trisubstituted-1,2,4-triazoles 605Ikizler et al., 2000; Demirbas et al., 2002, 2005; Demirbas and
Ugurluoglu, 2004; Bayrak et al., 2009). This paper reports on
the synthesis of a series of some new substituted amino-1,2,4-
triazoles via the reaction of C-phenylaminocarbonyl-N-
arylnitrilimines with guanidine derivatives, and investigates
the spectra of potential biological activities involved in the
process.2. Experimental
2.1. Material and instruments
Melting points were taken in open capillary tubes on
Gallenkamp apparatus and were uncorrected. Infrared spectra
were obtained by means of a Pye Unicam SP-3000 infrared
spectrophotometer using a KBr disk technique. The 1H
NMR and 13C NMR spectra were measured on a Bruker
AM 300 MHz spectrometer at room temperature in CDCl3
or DMSO-d6 solution using tetramethylsilane (TMS) as the
internal reference. Chemical shifts were recorded as d values
in parts per million (ppm) downﬁeld from internal TMS. Elec-
tron impact (EI) mass spectra were run on a Shimadzu GCMS-
QP1000 EX spectrometer at 70 eV. Elemental analyses were
performed at Cairo University, Egypt, and the results
agreed with the calculated values within experimental errors.
The hydrazonoyl halides 1(Frohberg et al., 2002) were
prepared according to well-established procedures in the
literature. Guanidine and diphenylguanidine hydrochloride,
tetrahydrofuran (THF), and triethylamine were purchased
from Avocado Research Chemicals, England, and used
without further puriﬁcation.
2.2. Synthesis of 1,3,5-trisubstituted-1,2,4-triazoles (5a–j)
To a stirred solution of the hydrazonoyl halides (10 mmol) in
THF (50 mL) was added a solution of guanidine hydrochloridederivatives (15 mmol) in methanol (30 ml). To the resulting
reaction mixture, cooled in an ice-salt bath (5–0 C), was
dropwise added triethylamine (50 mmol). After addition was
complete, stirring was continued for 1 h at 0 C, and then at
room temperature over night. The solvent was removed under
reduced pressure, and the residue was washed with water
(50 mL) to remove triethylammonium salt. The resulting crude
solid product was collected and recrystallized from methanol
or ethanol to give the desired good yields of the products
5a–j. The physical and analytical data of the title compounds
are given in Table 1.
2.2.1. 5-Amino-3-carbanlino-1-phenyl-1,2,4-triazole (5a)
IR (m/cm1): 3430, 3428, 3352 (NH2 and NH), 1660 (C‚O),
1622, 1618 (C‚N); 1H NMR (d/ppm): 9.20 (s, 1H, NH
amide), 8.23 (s, 2H, NH2), 7.60–7.10 (m, 10H, Ar-H);
13C
NMR (d/ppm): 161.7 (C‚O), 152.2, 150.8 (C‚N), 140.9,
136.9, 129.6, 129.2, 128.7, 127.2, 125.2, 119.7 (C‚C, Ar).
2.2.2. 5-Amino-3-carbanlino-1-(4-chlorophenyl)-1,2,4-triazole
(5b)
IR (m/cm1): 3426, 3424, 3351 (NH2 and NH), 1665 (C‚O),
1625, 1621 (C‚N); 1H NMR (d/ppm): 9.20 (s, 1H, NH
amide), 8.31 (s, 2H, NH2), 7.89 (d, J= 8.6 Hz, 2H, Ar-H),
7.90–7.21 (m, 5H, Ar-H), 7.44 (d, J= 8.6 Hz, 2H, Ar-H);
13C NMR (d/ppm): 161.9 (C‚O), 153.5, 151.3 (C‚N),
140.5, 138.8, 136.4, 132.5, 129.3, 129.1, 126.2, 116.2 (C‚C,
Ar).
2.2.3. 5-Amino-1-(4-bromophenyl)-3-carbanlino-1,2,4-triazole
(5c)
IR (m/cm1): 3434, 3431, 3348 (NH2 and NH), 1663 (C‚O),
1620, 1616 (C‚N); 1H NMR (d/ppm): 9.20 (s, 1H, NH
amide), 8.30 (s, 2H, NH2), 7.84 (d, J= 8.3 Hz, 2H, Ar-H),
7.74–7.16 (m, 5H, Ar-H) 7.50 (d, J= 8.3 Hz, 2H, Ar-H); 13C
NMR (d/ppm): 161.7 (C‚O), 152.4, 150.9 (C‚N), 140.3,
137.5, 131.2, 128.7, 126.6, 124.5, 120.8, 118.5 (C‚C, Ar).
606 H.M.M. Dalloul2.2.4. 5-Amino-3-carbanlino-1-(4-ﬂuorophenyl)-1,2,4-triazole
(5d)
IR (m/cm1): 3422, 3418, 3350 (NH2 and NH), 1660 (C‚O),
1626, 1622 (C‚N); 1H NMR (d/ppm): 9.20 (s, 1H, NH
amide), 8.38 (s, 2H, NH2), 7.98 (d, J= 8.7 Hz, 2H, Ar-H),
7.87–7.22 (m, 5H, Ar-H), 7.54 (d, J= 8.7 Hz, 2H, Ar-H);
13C NMR (d/ppm): 162.3 (C‚O), 153.6, 151.4 (C‚N),
141.0, 139.9, 137.5, 136.8, 128.7, 126.5, 120.9, 115.7 (C‚C,
Ar).
2.2.5. 5-Amino-3-carbanlino-1-(4-methylphenyl)-1,2,4-triazole
(5e)
IR (m/cm1): 3428, 3425, 3345 (NH2 and NH), 1665 (C‚O),
1621, 1612 (C‚N); 1H NMR (d/ppm): 9.20 (s, 1H, NH
amide), 8.20 (s, 2H, NH2), 7.44 (d, J= 7.6 Hz, 2H, Ar-H),
7.62–6.86 (m, 5H, Ar-H), 7.44 (d, J= 7.6 Hz, 2H, Ar-H),
2.73 (s, 3H, CH3);
13C NMR (d/ppm): 161.2 (C‚O), 152.2,
150.1 (C‚N), 140.9, 136.9, 129.5, 129.2, 128.8, 127.3, 125.1,
119.8 (C‚C, Ar), 21.7 (CH3).
2.2.6. 3-Carbanlino-1-phenyl-5-phenylmino-1,2,4-triazole (5f)
IR (m/cm1): 3420, 3349 (N–H), 1655 (C‚O), 1615, 1608
(C‚N); 1H NMR (d/ppm): 9.20 (s, 1H, NH amide), 8.50 (s,
1H, NH), 7.70–7.20 (m, 15H, Ar-H); 13C NMR (d/ppm):
161.6 (C‚O), 153.4, 151.8 (C‚N), 141.4, 138.6, 138.1,
136.3, 132.6, 129.9, 129.3, 128.9, 128.7, 127.3, 125.1, 119.8
(C‚C, Ar).
2.2.7. 3-Carbanlino-1-(4-chlorophenyl)-5-phenylmino-1,2,4-
triazole (5g)
IR (m/cm1): 3418, 3344 (N–H), 1652 (C‚O), 1620, 1610
(C‚N); 1H NMR (d/ppm): 9.20 (s, 1H, NH amide), 8.54 (s,
2H, NH), 7.83 (d, J= 8.5 Hz, 2H, Ar-H), 7.78–7.61 (m,
10H, Ar-H), 7.42 (d, J= 8.5 Hz, 2H, Ar-H); 13C NMR (d/
ppm): 161.6 (C‚O), 153.7, 151.6 (C‚N), 140.7, 138.7,
138.1, 136.4, 132.6, 129.3, 129.1, 128.9, 127.6, 126.3, 125.1,
119.8 (C‚C, Ar).
2.2.8. 1-(4-Bromophenyl)-3-carbanlino-5-phenylmino-1,2,4-
triazole (5h)
IR (m/cm1): 3421, 3347 (N–H), 1657 (C‚O), 1618, 1604
(C‚N); 1H NMR (d/ppm): 9.20 (s, 1H, NH amide), 8.52YH
Cl(Br)
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Scheme 1 Synthetic pathway for the(s, 1H, NH), 7.85 (d, J= 8.1 Hz, 2H, Ar-H), 7.66–7.16 (m,
10H, Ar-H), 7.52 (d, J= 8.0 Hz, 2H, Ar-H); 13C NMR (d/
ppm): 161.7 (C‚O), 152.8, 150.7 (C‚N), 140.6, 139.6,
137.5, 135.1, 131.3, 128.8, 128.6, 127.8, 126.6, 124.6, 120.8,
118.7 (C‚C, Ar).
2.2.9. 3-Carbanlino-1-(4-ﬂuorophenyl)-5-phenylmino-1,2,4-
triazole (5i)
IR (m/cm1): 3424, 3345 (NH), 1655 (C‚O), 1622, 1612
(C‚N); 1H NMR (d/ppm): 9.20 (s, 1H, NH amide), 8.58 (s,
1H, NH), 7.90 (d, J= 8.8 Hz, 2H, Ar-H), 7.86–7.26 (m,
10H, Ar-H), 7.56 (d, J= 8.8 Hz, 2H, Ar-H); 13C NMR (d/
ppm): 161.9 (C‚O), 153.8, 151.9 (C‚N), 140.9, 139.9,
137.5, 136.9, 128.8, 128.6, 128.2, 127.0, 126.6, 124.6, 121.0,
115.4 (C‚C, Ar).
2.2.10. 3-Carbanlino-1-(4-methylphenyl)-5-phenylmino-1,2,4-
triazole (5j)
IR (m/cm1): 3422, 3343 (NH), 1650 (C‚O), 1617, 1608
(C‚N); 1H NMR (d/ppm): 9.20 (s, 1H, NH amide), 8.55 (s,
1H, NH), 7.44 (d, J= 7.4 Hz, 2H, Ar-H), 7.73–6.93 (m,
10H, Ar-H), 7.44 (d, J= 7.4 Hz, 2H, Ar-H), 2.72 (s, 3H,
CH3);
13C NMR (d/ppm): 160.9 (C‚O), 152.6, 150.5
(C‚N), 141.1, 138.6, 138.1, 136.6, 132.6, 129.4, 129.3, 129.1,
128.7, 126.6, 125.1, 119.3 (C‚C, Ar), 21.7 (CH3).3. Results and discussion
The generation of the nitrilimine intermediate 2 was accom-
plished in situ by treatment of the corresponding hydrazonoyl
chloride 1 with triethylamine in the presence of the dipolaro-
phile, guanidine and diphenylguanidine hydrochloride 3. The
reaction led to the formation of 1,3,5-trisubstituted-1,2,4-tria-
zole derivatives 5a–j (Scheme 1). Both analytical and spectro-
scopic data (IR, 1H NMR, 13C NMR and MS) of the
synthesized compounds were in full agreement with the pro-
posed structures.
The formation of compounds (5a–j) is assumed to involve
the formation of 5,5-diamino-1,2,4-triazoles 4 (Scheme 1),
through nucleophilic addition of the electron pair of the imino
group of guanidine then cyclization at the imine carbon, or by
cycloaddition onto C‚N of the guanidine moiety or (group).NH
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Table 2 Antimicrobial screening results of the tested compounds.*
Comp. No. Antibacterial activity Antifungal activity
Euterococci Escherichia coli Staphylococcus aureus Candida albicans Aspergillus niger
5a 16 17 16 15 14
5b 17 18 16 17 18
5c 14 15 13 18 16
5d 19 18 17 19 12
5e 16 19 16 17 11
5g 15 12 14 16 9
5h 16 17 17 15 14
5i 19 18 19 17 18
DMF – – – – –
* Zone of inhibition in mm.
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ultimately undergoes the elimination of ammonia or aniline
molecule yielding the aromatic 1,2,4-triazole derivatives 5a–j
as outlined in the Scheme 1.
It is worth mentioning that the same nitrilimines 2 are
found to react with acetamidine, benzamidine, benzylthio-
formamidine, and acetaldoxime in cycloaddition processes to
give 1,3,5-trisubstituted 1,2,4-triazoles 6 through the elimina-
tion of ammonia or water molecules as shown in Scheme 2
(Dalloul, 2009).
3.1. Spectral data analysis
The assignment of structures of compounds 5a–j is based on
their analytical and spectroscopic data. Physical properties,
molecular ion peaks and microanalysis are presented in Table
1. The electron impact (EI) mass spectra of these compounds
5a–j displayed the correct molecular ions (M+) in accordance
with the suggested structures (Table 1). Their IR spectra
showed strong absorption bands of NH in the region
3430–3340 cm1, in addition to, the characteristic band of
amide C‚O at about 1660–1650 cm1 and C‚N of triazole
ring in the region of 1620–1600 cm1. The 1H NMR conﬁrmed
the formation of compounds 5a–j their spectra showed, in
addition to aromatic protons signals, a characteristic signal
due to the NH proton at C-5 of the ring resonating as a singlet
at 8.6–8.2 ppm and the amide NH appeared as a singlet in therange of 8.9–8.8 ppm. The structures of compounds 5a–j were
further conﬁrmed by 13C NMR spectra, which account for the
different carbons of these triazoles. The signals at about
153–151 ppm were attributed to the C-3 and C-5 carbons of
the triazole ring, and are in accordance with reported values
of azo-methine carbons in ﬁve-membered heterocycles
(Dalloul et al., 2008; Dalloul, 2009). The 1H and 13C NMR
spectral data of the synthesized compounds are presented in
the experimental part.
3.2. Antimicrobial activity
Most of the newly synthesized compounds were tested for their
antibacterial and antifungal activities in vitro against bacterial
strains such as Escherichia coli, Staphylococcus aureus, Pseudo-
monas aeruginosa and Aspergillus ﬂavus, and Candida albicans
as fungi. The compounds tested at a concentration of 1–10 mg/
mL in N,N-dimethylformamide (DMF) solution, using the
nutrient agar disc diffusion method (Collins et al., 1989) and
measuring the average diameter of the inhibition zone in
mm. The results showed that all the tested compounds
exhibited a marked degree of activity against bacteria and
fungi compared with well known antibacterial and antifungal
substances such as tetracycline and ﬂuconazole. According to
NCCLS (2004), zones of inhibition for tetracycline and
ﬂuconazole <14 mm were considered resistant, between 15
and 18 mm were considered weakly sensitive and >19 mm
608 H.M.M. Dalloulwere considered sensitive. Also, the results showed the degree
of inhibition varied with the tested compounds (Table 2).
4. Conclusion
In conclusion, the reaction of nitrilimines with guanidine and
diphenyl-guanidine hydrochloride leads to the formation of
aromatic heterocyclic triazoles in one step, and some of them
proved to have potent antibacterial and antifungal activities.
The results conﬁrm that the antimicrobial activity is strongly
dependent on the nature of the substituents at the triazole ring.
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